After patients with stage IIIA NSCLC are treated with NCI, increasing B cells and CD4+ T cells based on single-cell RNA-sequencing analysis from radical surgery samples have been found to be associated with a positive therapeutic response [41]. The gene discussed is CD4; the disease is non-small cell lung carcinoma.